CAP Drugs Must Meet Stricter Noninferiority Criteria Under Draft FDA Guidance
Executive Summary
Biopharma firms developing drugs to treat community acquired pneumonia would be wise to follow the specifications FDA has set forth in a new 1draft guidance on the subject. The guidance specifies strict criteria for patient selection and confirmation of infection to support an evaluation based on noninferiority margins
You may also be interested in...
FDA Indicates Flexibility On Evidence To Support Efficacy In Pneumonia
The agency will seek advisory panel input Nov. 3-4 on options for facilitating trials in community-, hospital- and ventilator-acquired pneumonia.
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.
Pneumonia Guidances Revisited: FDA Cmte. To Weigh Study Design Issues Again
FDA’s Anti-Infective Drugs Advisory Committee will take its third look in less than four years at standards for developing antibacterial agents to treat community-acquired bacterial pneumonia, at a meeting on Nov. 3.